Skip to main content
. 2012 Jan 12;11:5. doi: 10.1186/1477-5751-11-5

Table 4.

NGFR haplotypes and the risk of Alzheimer's disease

Haplotype Frequency
among controls
(%)
Co-dominant model

0 copies 1 copy 2 copies



Case/control OR Case/control OR (95% CI) p Case/control OR (95% CI) p
Hap1: GCGCG 27.8 148/203 1.00 105/156 0.82 (0.54-1.25) 0.36 11/30 0.39 (0.17-0.91) 0.03
Hap2: GCTTG 21.9 159/234 1.00 90/140 0.94 (0.61-1.47) 0.79 15/15 1.01 (0.42-2.42) 0.99
Hap3: GCTTA 11.5 205/305 1.00 56/78 1.09 (0.65-1.84) 0.74 3/6 1.38 (0.27-6.97) 0.70
Hap4: GCTCA 11.3 197/304 1.00 65/81 1.37 (0.83-2.27) 0.22 2/4 0.94 (0.11-7.94) 0.95
Hap5: GTTCG 10.3 213/312 1.00 47/74 1.37 (0.81-2.33) 0.23 4/3 3.59 (0.66-19.42) 0.14
Hap6: GCTCG 8.9 217/323 1.00 46/63 0.97 (0.54-1.73) 0.92 1/3 0.18 (0.01-5.26) 0.32
Hap7: TCTCG 5.6 230/347 1.00 34/40 1.15 (0.63-2.12) 0.65 0/2 NA

Global test P = 0.27

Global test was testing for the null hypothesis that none of the haplotype was associated with AD risk.

Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable.